(E)-3-(2-amino-4-chlorophenyl)-acrylic acid | 868407-50-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(2-amino-4-chlorophenyl)-acrylic acid
• 英文别名: (E)-3-(2-amino-4-chlorophenyl)prop-2-enoic acid
• CAS: 868407-50-5
• 化学式: C₉H₈ClNO₂
• 分子量: 197.621
• InChiKey: IJDAAMAVIKGCRP-DUXPYHPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(2-amino-4-chlorophenyl)-acrylic acid 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 (R,E)-3-((5-chloro-2-(3-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-3-oxoprop-1-en-1-yl)phenyl)amino)-4-ethoxycyclobut-3-ene-1,2-dione
  参考文献：
  名称：

  Structure–activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

  摘要：

  Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCRI antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.104
• 作为产物：
  描述：

  methyl (E)-3-(2-amino-4-chlorophenyl)acrylate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以95%的产率得到(E)-3-(2-amino-4-chlorophenyl)-acrylic acid
  参考文献：
  名称：

  Structure–activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

  摘要：

  Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCRI antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.104

文献信息

• ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160264518A1

  公开（公告）日：2016-09-15

  The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

  本发明涉及组蛋白去乙酰化酶抑制剂，特别是HDAC8，用于治疗癌症和其他疾病和疾病，以及所述抑制剂的合成和应用。
• Compounds As Ccri Antagonists
  申请人：Heng Richard

  公开号：US20070196270A1

  公开（公告）日：2007-08-23

  A compound of formula I, or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.

  化合物I的公式，或其药学上可接受的盐或酯，其中符号的含义如定义的那样，它们是CCR-1的拮抗剂，并且在药学上用于治疗与CCR-1有关的疾病和症状，例如炎症性疾病。
• 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE
  申请人：Nishi Tatsuya

  公开号：US20120245152A1

  公开（公告）日：2012-09-27

  A compound of the general formula (I): [wherein, R 1 represents a halogen atom, or the like, R 2 represents a hydrogen atom, or the like, R 3 and R 4 , each independently, represent a hydrogen atom, a C 1-4 alkyl group, or the like, R 5 represents a hydrogen atom, a halogen atom, or the like, R 6 represents a hydrogen atom, a halogen atom, or the like, R 7 and R 8 , each independently, represent a hydrogen atom, a halogen atom, or the like, R 9 and R 10 , each independently, represent a hydrogen atom, a C 1-4 alkyl group, R 11 and R 12 , each independently, represent a hydrogen atom, a C 1-4 alkyl group, or the like, X represents an oxygen atom, a group —CH 2 —, or the like, Y represents a nitrogen atom, a group ═CH—, or the like, and Z represents a nitrogen atom, or the like] or a pharmacologically acceptable salt thereof, which has an excellent suppressive action on platelet aggregation, and is useful for prevention and/or treatment of thromboembolism.

  一种具有一般式（I）的化合物：[其中，R1代表卤素原子或类似物，R2代表氢原子或类似物，R3和R4各自独立地代表氢原子、C1-4烷基或类似物，R5代表氢原子、卤素原子或类似物，R6代表氢原子、卤素原子或类似物，R7和R8各自独立地代表氢原子、卤素原子或类似物，R9和R10各自独立地代表氢原子、C1-4烷基，R11和R12各自独立地代表氢原子、C1-4烷基或类似物，X代表氧原子、-CH2-基团或类似物，Y代表氮原子、═CH-基团或类似物，Z代表氮原子或类似物]或其药学上可接受的盐，具有出色的抑制血小板聚集作用，可用于预防和/或治疗血栓栓塞。
• 3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2471792A1

  公开（公告）日：2012-07-04

  A compound of the general formula (I): [wherein, R1 represents a halogen atom, or the like, R2 represents a hydrogen atom, or the like, R3 and R4, each independently, represent a hydrogen atom, a C1-4 alkyl group, or the like, R5 represents a hydrogen atom, a halogen atom, or the like, R6 represents a hydrogen atom, a halogen atom, or the like, R7 and R8, each independently, represent a hydrogen atom, a halogen atom, or the like, R9 and R10, each independently, represent a hydrogen atom, a C1-4 alkyl group, R11 and R12, each independently, represent a hydrogen atom, a C1-4 alkyl group, or the like, X represents an oxygen atom, a group -CH2-, or the like, Y represents a nitrogen atom, a group =CH-, or the like, and Z represents a nitrogen atom, or the like] or a pharmacologically acceptable salt thereof, which has an excellent suppressive action on platelet aggregation, and is useful for prevention and/or treatment of thromboembolism.

  通式(I)的化合物： [其中，R1 代表卤原子或类似物，R2 代表氢原子或类似物，R3 和 R4 各自独立地代表氢原子、C1-4 烷基或类似物，R5 代表氢原子、卤原子或类似物，R6 代表氢原子、卤原子或类似物，R7 和 R8 各自独立地代表氢原子、卤原子或类似物，R9 和 R10 各自独立地代表氢原子、R11和R12各自独立地代表氢原子、C1-4烷基或类似基团，X代表氧原子、基团-CH2-或类似基团，Y代表氮原子、基团=CH-或类似基团，Z代表氮原子或类似基团]或其药理上可接受的盐，对血小板聚集有很好的抑制作用，可用于预防和/或治疗血栓栓塞。
• Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
  申请人：FORMA Therapeutics, Inc.

  公开号：US10266487B2

  公开（公告）日：2019-04-23

  The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

  本发明涉及组蛋白去乙酰化酶（尤其是 HDAC8）的抑制剂，可用于治疗癌症及其他疾病和失调，还涉及上述抑制剂的合成和应用。